GLP-1 Safety During Pregnancy: What Research Shows

Last reviewed: May 26, 2026

Last updated: May 26, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

No, GLP-1 medications are not recommended during pregnancy. Current clinical guidelines from the American College of Obstetricians and Gynecologists (ACOG) advise discontinuing GLP-1 receptor agonists before conception due to limited human safety data in pregnant populations.

Pregnancy planning requires a comprehensive approach to metabolic health. Understanding your individual genetic predispositions and metabolic risk factors can help you and your provider develop a safe, personalized strategy for managing weight and blood sugar stability before and during pregnancy.

Why GLP-1 Medications Are Contraindicated in Pregnancy

GLP-1 receptor agonists were not studied in human pregnancy trials. Regulatory agencies classify these medications as Category C (limited animal data) or recommend avoiding them during pregnancy due to precautionary principles and lack of controlled human evidence.

Animal studies have shown mixed results, with some suggesting potential effects on fetal development. Because human pregnancy involves complex hormonal and metabolic changes, extrapolating animal data to humans is unreliable, making clinical caution the appropriate standard.

GLP-1 Discontinuation Timeline and Planning Considerations

If you are taking a GLP-1 medication and planning pregnancy, work with your obstetric provider to establish a safe discontinuation schedule. Stopping abruptly may cause blood sugar fluctuations, so a gradual tapering plan is typically recommended.

The timing of discontinuation depends on the specific medication, your glucose control, and your health history. Planning this transition 2–3 months before attempting conception allows metabolic stabilization on alternative approaches.

Consideration	Timeline & Action
Schedule provider consultation	As soon as pregnancy is planned—at least 2–3 months before conception
Medication tapering	Gradual reduction over weeks, not abrupt cessation, to prevent metabolic instability
Baseline glucose and HbA1c testing	Before discontinuation to establish metabolic baseline
Alternative management strategies	Nutrition, exercise, stress management, and medical options approved for pregnancy discussed in advance
Genetic and biomarker assessment	Consider completing Precision Peptide Genetic Test to understand metabolic predispositions before pregnancy

Evidence-Based Alternatives During Pregnancy Planning and Gestation

Lifestyle interventions—structured nutrition plans, regular physical activity, and stress management—form the foundation of metabolic health during pregnancy. These approaches have decades of evidence supporting safety and effectiveness in managing gestational glucose tolerance.

Metformin is the only oral diabetes medication considered safe in pregnancy and is often recommended for gestational diabetes management. For weight management without medications, behavioral support and specialized prenatal nutrition programs can help maintain metabolic stability.

When to Restart GLP-1 Medications: Postpartum Considerations

GLP-1 medications can typically be restarted after pregnancy. Current guidelines do not contraindicate use during breastfeeding, though very limited data exists; discuss timing with your obstetric provider and pediatrician.

The postpartum period presents an opportunity to reassess your metabolic health through testing and genetic insights. Understanding your peptide pathway predispositions can inform a more targeted reintroduction strategy when you and your provider determine the appropriate time.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual metabolic predispositions in GLP-1 and appetite-regulation pathways before conception planning. Knowledge of key genetic variants (such as GLP1R rs6923761, GIPR rs1800437, and FTO rs9939609) can support a more informed conversation with your obstetric team about your baseline metabolic risk profile.

The genetic test reveals predispositions in peptide-related pathways, not exact medication response or pregnancy outcomes. These insights should be interpreted with a qualified healthcare provider and integrated into a comprehensive pregnancy planning strategy that includes glucose tolerance testing, lifestyle assessment, and medical history review.

By understanding your metabolic predispositions before pregnancy, you can work with your provider to establish safer, more personalized alternatives to GLP-1 medications—including targeted nutrition, movement, stress management, and evidence-based pharmacotherapy appropriate for gestation.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at from $209/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.